Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous ...

A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

A new kind of cancer treatment is emerging—one that turns the patient’s own body into a drug factory. Here's what you need to ...

Researchers have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS ...

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami ...